The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Clearance pathways and what renal impairment changes

This is a generated summary. It shows the 5 most-liked posts from a topic of 16, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
AD
ambient_draftTL3Regular22 Nov 2025#3
ai.wikstrom, post #2: A request rather than an answer: could whoever has the primary source for clearance pathways post it? I have seen the claim three times this month and each version had lost a qualifier. Go to post

Everything in the opening post holds. The case it does not cover is the one I have.

Renal impairment changes clearance for some compounds in this class and not others, and the published data is compound-specific rather than class-wide.

Nothing above should be read as advice about what anyone else should do.

18 likes in reply to #2 8mo
P
PWendelboeTL1Member27 Jan 2026#7
ak.kravchenko, post #4: Narrowing the opening post, because the general version has more than one answer. Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available. That is all I can say… Go to post

Answering the question post #5 raises rather than the one it answers.

Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability.

I am confident about the direction and much less about the magnitude.

25 likes in reply to #4 6mo
CN
c.nybergTL210 Feb 2026#8
ak.kravchenko, post #4: Narrowing the opening post, because the general version has more than one answer. Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available. That is all I can say… Go to post

The useful distinction on clearance pathways is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.

12 likes in reply to #4 6mo
MA
m.amankwahTL224 Mar 2026#11

Adding what did not work for me on clearance pathways, since the failures never get written up and they are half the useful information.

20 likes 4mo
I
IMainwaringTL3Regular1 May 2026#14

Hepatic metabolism: the degree to which each compound is hepatically metabolised versus renally cleared is known but varies. Severe liver disease changes clearance.

9 likes 3mo

Read the full topic (16 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Subcutaneous absorption kinetics and site differences
Posting this under the heading it deserves: Subcutaneous absorption kinetics and site differences Everything below is what sits behind that. Asking about subcutaneous absorption kinetics and site directly,…
NRVRMRNSS+15 19 3.9k 12mo
Coming back to: Washout: how long is long enough, and for what purpose
Posting this under the heading it deserves: Washout: how long is long enough, and for what purpose Everything below is what sits behind that. A narrow question about Washout, deliberately narrow, because the…
AWBWCEAWS+128 139 3k 3mo
Half-life, steady state, and accumulation worked through
Half-life, steady state, and accumulation worked through Writing it up because I had to work it out twice and would rather nobody else did. Working through the kinetics rather than the pharmacology, because I…
OVJSRPTS+115 130 44k 13mo
Follow-up: Subcutaneous absorption kinetics and site differences
Subcutaneous absorption kinetics and site differences — setting out what I have, and where I think it stops being reliable. A follow-up question about Subcutaneous absorption kinetics and site that I did not…
HCFPNVBICM 4 9.9k 10mo
Half-life, steady state, and accumulation worked through — a second dataset
Half-life, steady state, and accumulation worked through — a second dataset — setting out what I have, and where I think it stops being reliable. Working through the kinetics rather than the pharmacology,…
EDRFCHLIAK+110 126 14k 4mo

Related topics — sharing the tags missed dose, liraglutide, tirzepatide

TopicParticipantsRepliesViewsActivity
Reading U-100 graduations, with a conversion table
Posting this under the heading it deserves: Reading U-100 graduations, with a conversion table Everything below is what sits behind that. A question about reading U-100 graduations that I think has a definite…
YERDKFKVKP+35 41 2k 1d
Drawing up with one needle and injecting with another
On the subject in the title: Drawing up with one needle and injecting with another Working notes rather than a conclusion. A question about technique rather than about dose. I have been doing the same thing…
KFIDFIOCH+1 5 6.9k 1d
Storing a pen in use versus a pen unopened — what changed since
Posting this under the heading it deserves: Storing a pen in use versus a pen unopened — what changed since Everything below is what sits behind that. What changes if the standard account of Storing a pen is…
EFDWMD 2 206 15mo
Second pass at: Regression to the mean in progress reports
Second pass at: Regression to the mean in progress reports Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on Regression. It is mine, it is…
SGCKIAMDM+71 75 4k 17mo
About the Pens & autoinjectors category
Pen mechanics, dose counters, priming, and what happens when a pen is used off its label. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
TVHSJASSIW+1 5 92 5mo